entecavir

Entecavir (SQ34676) is a guanosine nucleoside analogue used in the treatment of chronic hepatitis B virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis B during or after therapy, but has not been linked to cases of clinically apparent liver injury.

ent-Entecavir is an enantiomeric impurity of the antiviral drug Entecavir. Entecavir is an oral antiviral drug used in the treatment of hepatitis B virus (HBV) infection. Entecavir is a reverse transcriptase inhibitor. It prevents the hepatitis B virus from multiplying and reduces the amount of virus in the body. More specifically, it is a deoxyguanosine analogue belonging to a class of carbocyclic nucleosides, that inhibits reverse transcription, DNA replication and transcription in the viral replication process.

Entecavir monohydrate (BMS-200475) is a selective inhibitor of the replication of the hepatitis B virus (HBV). It, a new deoxyguanine nucleoside analog.

Entecavir-9 is a useful organic compound for research related to life sciences. The catalog number is T65556 and the CAS number is 142217-81-0.

Entecavir-13C2,15N (BMS200475-13C2,15N; SQ34676-13C2,15N) is a version of Entecavir labeled with 13C and 15N isotopes. Entecavir (SQ 34676; BMS 200475) acts as a selective and effective inhibitor of HBV, demonstrating an EC50 value of 3.75 nM in HepG2 cells.

TLR8 agonist 4 was effective in inhibiting both wild-type and drug-resistant (lamivudine and entecavir) HBV strains with their IC50 values of 0.15 and 0.10 μM, respectively.